Please login to the form below

Not currently logged in
Email:
Password:

Teva acquires Taiyo for almost $1bn

Teva Pharmaceutical has completed the full acquisition of Japanese generics manufacturer Taiyo in a cash deal worth $934m

Teva Pharmaceutical has completed the full acquisition of Japanese generics manufacturer Taiyo in a cash deal worth $934m.

The agreement follows Israel-based Teva's agreement in May 2011 to acquire 57 per cent of the share held in Taiyo for $460m in cash.

Teva is already the largest generics company in the world, and will add a portfolio of over 550 products and a strong Japanese presence to its business.

Taiyo currently has annual sales of around $530m in a market where generic penetration is relatively low but is being actively encouraged by the Japanese government.

According the Teva, the company expects to reach $1bn in sales in Japan, ahead of its original 2015 target.

Teva president and CEO, Shlomo Yanai, described the acquisition as an "important milestone" for the company.

He continued: "The acquisition of Taiyo, along with Teva's existing Japanese business, assures that Teva will deliver on our strategic objective of becoming a leading player in Japan."

14th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics